Taiwan - Delayed Quote TWD

Bionime Corporation (4737.TW)

61.50
+1.50
+(2.50%)
At close: May 9 at 1:30:35 PM GMT+8
Loading Chart for 4737.TW
  • Previous Close 60.00
  • Open 58.10
  • Bid 61.50 x --
  • Ask 61.60 x --
  • Day's Range 58.10 - 61.50
  • 52 Week Range 47.45 - 72.50
  • Volume 38,006
  • Avg. Volume 34,084
  • Market Cap (intraday) 3.74B
  • Beta (5Y Monthly) 0.29
  • PE Ratio (TTM) --
  • EPS (TTM) -2.09
  • Earnings Date --
  • Forward Dividend & Yield 2.00 (3.25%)
  • Ex-Dividend Date Jul 29, 2024
  • 1y Target Est --

Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Algeria, the United Arab Emirates, Egypt, and internationally. The company offers blood glucose meters and self-monitors, as well as accessories, such as test strips and lancing devices to medical equipment manufacturers, pharmacies, and hospitals. It is also involved in the provision of biotechnology services; drug testing; wholesale of precision instruments; and manufacturing of medical equipment, etc. Bionime Corporation was incorporated in 2003 and is based in Taichung, Taiwan.

www.bionime.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4737.TW

View More

Performance Overview: 4737.TW

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4737.TW
4.95%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
9.20%

1-Year Return

4737.TW
10.37%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
1.72%

3-Year Return

4737.TW
5.95%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
30.32%

5-Year Return

4737.TW
8.42%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
91.86%

Compare To: 4737.TW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4737.TW

View More

Valuation Measures

Annual
As of 5/8/2025
  • Market Cap

    3.65B

  • Enterprise Value

    6.43B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.89

  • Price/Book (mrq)

    1.94

  • Enterprise Value/Revenue

    3.33

  • Enterprise Value/EBITDA

    108.51

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -4.33%

  • Return on Assets (ttm)

    -1.63%

  • Return on Equity (ttm)

    -4.34%

  • Revenue (ttm)

    1.92B

  • Net Income Avi to Common (ttm)

    -83.24M

  • Diluted EPS (ttm)

    -2.09

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    387.35M

  • Total Debt/Equity (mrq)

    159.50%

  • Levered Free Cash Flow (ttm)

    -123.76M

Research Analysis: 4737.TW

View More

Company Insights: 4737.TW

Research Reports: 4737.TW

View More

People Also Watch